Compugen Gestion
Gestion contrôle des critères 4/4
Le PDG Compugen est Eran Ophir, nommé en Mar2020, a un mandat de 6.17 ans. La rémunération annuelle totale est $ 478.22K, composée du salaire de 42.1% et des bonus 57.9%, y compris les actions et options de la société. détient directement 0.012% des actions de la société, d'une valeur de $ 31.05K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.2 ans et 8.5 ans.
Informations clés
Eran Ophir
Directeur général
US$478.2k
Rémunération totale
| Pourcentage du salaire du PDG | 42.05% |
| Durée du mandat du directeur général | 6.2yrs |
| Propriété du PDG | 0.01% |
| Durée moyenne d'occupation des postes de direction | 2.2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 8.5yrs |
Mises à jour récentes de la gestion
Recent updates
Seeking Alpha • May 19
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program
Summary Compugen (CGEN) is maintained at a "Buy" rating, driven by advancing clinical programs and upcoming catalysts in oncology. Rilvegostomig, partnered with AstraZeneca, is being evaluated in 11 phase 3 studies, with strong phase 1b/2 data in HER2+ gastric cancer [70% cORR]. New data from DESTINY-Gastric03 will be presented at ASCO 2026, and interim analysis for COM701 in ovarian cancer is expected Q1 2027. CGEN has a cash runway into 2029, with $134.9M on hand and potential for $1B in milestone payments from AstraZeneca and Gilead partnerships. Read the full article on Seeking Alpha
Mise à jour du récit • May 03
CGEN: Future Upside Will Rely On Sustained Long Term Execution Confidence
Analysts have maintained their $13.00 price target on Compugen, citing recent bullish initiation and supportive research as reasons to keep their outlook. This remains the case despite slight adjustments to assumptions for the discount rate, revenue growth, profit margin, and future P/E.Mise à jour du récit • Apr 07
CGEN: Future Upside Will Depend On Sustained Long Term Earnings Potential
Analysts maintained their target for Compugen at $13.00, citing updated assumptions that now reflect a slightly higher discount rate, a modestly weaker revenue growth outlook, a small reduction in expected profit margin, and a very large projected future P/E multiple. Valuation Changes Fair Value: Target remains at $13.00, with no change from the prior estimate.Mise à jour du récit • Mar 22
CGEN: Unchanged US$13 Fair Value Will Rely On Long Term Earnings
Analysts kept their $13.00 price target for Compugen unchanged, with only small tweaks to underlying inputs such as discount rate, revenue growth assumptions, profit margin, and very large future P/E expectations supporting the decision to maintain the prior valuation view. Valuation Changes Fair Value: $13.00 fair value is unchanged, signaling no revision to the overall price target level.Mise à jour du récit • Mar 06
CGEN: Royalty Monetization And Immuno Oncology Pipeline Will Drive Future Upside
Analysts have reiterated a $13.00 price target on Compugen, citing updated assumptions that include a slightly higher discount rate, a shift to an 11% revenue contraction, a lower profit margin near 12%, and a very large forward P/E estimate as the basis for their current stance. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, amending their 2018 exclusive license agreement to support Compugen's balance sheet and immuno oncology pipeline (Key Developments).
Nouveau récit • Mar 03
Ovarian Trial Delays And Royalty Uncertainty Will Test This Long Runway Story
Catalysts About Compugen Compugen is a clinical stage immuno oncology company that uses a computational discovery engine to develop antibody based cancer therapies and out license assets to larger partners. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Feb 20
CGEN: Royalty Sale And Oncology Pipeline Will Support Future Upside
Analysts have kept their price target for Compugen steady at $13.00, citing relatively unchanged fair value assumptions alongside small tweaks to the discount rate, very large projected revenue growth and expected profit margins, as well as an updated future P/E estimate. What's in the News Compugen and MedImmune Limited, part of the AstraZeneca Group, signed Amendment Number 4 to their March 30, 2018 license agreement covering rilvegostomig, updating the economic terms of Compugen's royalty interest (Key Developments).Mise à jour du récit • Feb 06
CGEN: Royalty Monetization And Oncology Pipeline Will Drive Future Upside
Narrative Update on Compugen Analysts have kept their price target for Compugen steady at $13.00, citing only minor tweaks to assumptions around discount rate, very high projected revenue growth and profit margin that did not materially change their overall view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).Mise à jour du récit • Jan 23
CGEN: Future Upside Will Be Driven By Royalty Monetization Deal
Analysts have kept their fair value estimate for Compugen steady at $13.00, with only minor model tweaks to discount rates, revenue growth assumptions and future P/E, helping to refine rather than reset their overall price target view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from the cancer drug candidate rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).Mise à jour du récit • Jan 09
CGEN: Future Upside Will Be Driven By Expanded Immuno Oncology Partnerships
Analysts have maintained their price target for Compugen at $13.00. They cite updated assumptions for discount rates, revenue growth, profit margins and a very large future P/E multiple as the main factors supporting this unchanged view.Mise à jour du récit • Dec 14
CGEN: Future Revenue Trajectory Will Be Driven By Ongoing COM701 Program
Analysts have raised their price target on Compugen to 13.00 dollars from 13.00 dollars, citing sharply higher projected revenue growth, improved long term profit margins and a more favorable future earnings multiple, even after incorporating a slightly higher discount rate. What's in the News Pooled analysis of COM701 Phase 1 trials in 60 evaluable patients with platinum resistant ovarian cancer published as an abstract by the European Society of Medical Oncology, highlighting anti tumor activity and safety in heavily pre treated patients (ESMO abstract) Analysis details outcomes for patients deriving clinical benefit, including progression free survival data, and is based on data from prior COM701 studies in platinum resistant ovarian cancer (Company announcement) Additional year of follow up data on COM701 in platinum resistant ovarian cancer will be featured in an upcoming ESMO poster, expanding on the initial pooled findings (ESMO poster) Compugen estimates interim analysis results for the ongoing COM701 program to be available by year end 2026, guided by the anticipated enrollment rate (Company guidance) Valuation Changes Fair Value: Unchanged at 13.00 dollars per share, reflecting no revision to the base case price target.Article d’analyse • Oct 07
There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise
Compugen Ltd. ( NASDAQ:CGEN ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Article d’analyse • Oct 02
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Mise à jour du récit • Aug 08
AI And Immunotherapy Advances Will Define Oncology's Future
Upward revisions to Compugen's revenue growth and net profit margin forecasts have driven a notable increase in its consensus analyst price target, which has risen from $5.50 to $6.25. What's in the News Compugen dosed the first patient in a global randomized sub-trial (MAIA-ovarian), evaluating its potential first-in-class anti-PVRIG antibody COM701 as maintenance therapy for relapsed platinum sensitive ovarian cancer.Article d’analyse • May 25
Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically
One thing we could say about the analysts on Compugen Ltd. ( NASDAQ:CGEN ) - they aren't optimistic, having just made a...Article d’analyse • Apr 09
Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Compugen fair value estimate is US$1.77 Current share price of...Article d’analyse • Feb 26
Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 2.9x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...
Nouveau récit • Jan 26
COM701 Trial Will Present Future Opportunities, But Competitive Risks Remain
Strategic advancements in drug development and partnerships could significantly bolster earnings and create opportunities in less competitive markets.Article d’analyse • Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 4.1x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...Article d’analyse • May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
Compugen Ltd. ( NASDAQ:CGEN ) just released its first-quarter report and things are looking bullish. The results were...Article d’analyse • May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
Compugen Ltd. ( NASDAQ:CGEN ) shareholders won't be pleased to see that the share price has had a very rough month...Article d’analyse • Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Key Insights Compugen's estimated fair value is US$3.61 based on 2 Stage Free Cash Flow to Equity Compugen's US$2.32...Article d’analyse • Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Despite an already strong run, Compugen Ltd. ( NASDAQ:CGEN ) shares have been powering on, with a gain of 26% in the...Article d’analyse • Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, Compugen...Article d’analyse • Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Article d’analyse • Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Article d’analyse • Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Article d’analyse • Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 12
Compugen appoints Alberto Sessa as CFO
Clinical-stage cancer immunotherapy company Compugen (NASDAQ:CGEN) on Monday said it had appointed Alberto Sessa as its CFO. The appointment follows the departure of previous CFO Ari Krashin in May. Sessa will join CGEN on Nov. 1, 2022, the company said. According to CGEN, Sessa has more than 30 years of industry experience and most recently served as acting CFO at several startups in the high-tech industry. CGEN stock flat in mid-day trading.Seeking Alpha • Aug 24
Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Compugen (NASDAQ:CGEN) said that the Japan Patent Office granted a new composition of matter and use patent covering its anti-PVRIG, COM701 and backup anti-PVRIG antibodies. The Japanese patent No. 2017-562952 is expected to expire not before 2036. The company noted that in pre-clinical studies, blockade of PVRIG — a novel immune checkpoint — by COM701 has shown potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. CGEN +1.57% to $1.29 premarket Aug. 24Seeking Alpha • Aug 03
Compugen Q2 2022 Earnings Preview
Compugen (NASDAQ:CGEN) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close. The consensus EPS Estimate is -$0.11 (flat Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward.Article d’analyse • Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Article d’analyse • Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$35m |
| Dec 31 2025 | n/a | n/a | US$35m |
| Sep 30 2025 | n/a | n/a | -US$28m |
| Jun 30 2025 | n/a | n/a | -US$19m |
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$478k | US$201k | -US$14m |
| Sep 30 2024 | n/a | n/a | US$2m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | US$541k | US$196k | -US$19m |
Rémunération vs marché: La rémunération totale de Eran ($USD 478.22K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.74M ).
Rémunération et revenus: La rémunération de Eran a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Eran Ophir (47 yo)
6.2yrs
Titularisation
US$478,219
Compensation
Dr. Eran Ophir is CEO, President & Director of Compugen Ltd. from September 2025. Dr. Ophir was Senior Vice President of Research & Drug Discovery of Compugen Ltd.from March 2022 to 2023. Dr. Ophir was Vi...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chair | 12.3yrs | US$1.24m | 0.11% $ 296.5k | |
| CEO, President & Director | 6.2yrs | US$478.22k | 0.012% $ 31.1k | |
| Chief Operating Officer | 1.3yrs | US$604.00k | pas de données | |
| Senior Vice President of Business Development | 8.3yrs | US$461.80k | 0.031% $ 80.2k | |
| Chief Medical Officer | 2.2yrs | US$592.99k | 0.024% $ 63.1k | |
| Chief Financial Officer | 1.8yrs | pas de données | 0.038% $ 96.9k | |
| General Counsel & Corporate Secretary | 7.3yrs | pas de données | pas de données | |
| Vice President of Human Resources | 19.3yrs | pas de données | pas de données | |
| Vice President Research and Discovery | no data | pas de données | pas de données | |
| Senior Vice President of Research & Discovery | less than a year | pas de données | 0.021% $ 53.2k |
2.2yrs
Durée moyenne de l'emploi
48yo
Âge moyen
Gestion expérimentée: L'équipe de direction de CGEN est considérée comme expérimentée (ancienneté moyenne 2.2 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive Chair | 12.3yrs | US$1.24m | 0.11% $ 296.5k | |
| CEO, President & Director | less than a year | US$478.22k | 0.012% $ 31.1k | |
| Member of Scientific Advisory Board | 5.7yrs | pas de données | pas de données | |
| Independent Director | 7.9yrs | pas de données | 0.013% $ 34.6k | |
| Member of Scientific Advisory Board | 12.8yrs | pas de données | pas de données | |
| Independent Director | 7.9yrs | pas de données | 0.012% $ 31.1k | |
| Independent Director | 7.9yrs | pas de données | 0.014% $ 36.4k | |
| Chairman of Scientific Advisory Board | 12.3yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 12.8yrs | pas de données | pas de données | |
| Independent Director | 6.8yrs | pas de données | 0.011% $ 27.3k | |
| Member of Scientific Advisory Board | 12.8yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 9.2yrs | pas de données | pas de données |
8.5yrs
Durée moyenne de l'emploi
58yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de CGEN sont considérés comme expérimentés (ancienneté moyenne 8.5 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 19:02 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Compugen Ltd. est couverte par 10 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Ling Wang | Chardan Capital Markets, LLC |
| Michael King | Citizens JMP Securities, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |